Invitae Corporation (NYSE:NVTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02

On May25, 2017, Invitae Corporation (Invitae) announced the
appointment of Shelly Guyer as Chief Financial Officer, effective
June12, 2017. Ms.Guyer will also serve as Invitaes principal
financial officer. Upon her appointment, Invitaes current Chief
Financial Officer, Lee Bendekgey, will fully transition to the
role of Chief Operating Officer.

Ms.Guyer, age 56, most recently served as Chief Financial Officer
of Veracyte, Inc., a genomic diagnostics company, from April 2013
to December 2016 and served as Veracytes Secretary from April
2013 to March 2014. Previously, she served as Chief Financial
Officer and Executive Vice President of Finance and
Administration of iRhythm Technologies, Inc., a digital
healthcare company, from April 2008 to December 2012. From March
2006 to August 2007, Ms.Guyer served as Vice President of
Business Development and Investor Relations of Nuvelo Inc., a
biopharmaceutical company. Prior to joining Nuvelo, Ms.Guyer
worked at J.P. Morgan Securities and its predecessor companies
for over 17 years, serving in a variety of roles including in
healthcare investment banking. Ms.Guyer holds an A.B. in Politics
from Princeton University and an M.B.A. from the Haas School of
Business at the University of California, Berkeley.

In connection with Ms.Guyers appointment as Chief Financial
Officer, Invitae and Ms.Guyer entered into an offer letter
agreement dated May19, 2017 (the Offer Letter), to which Ms.Guyer
will be entitled to receive an initial annual base salary of
$425,000. Ms.Guyer was also granted an incentive stock option to
purchase 44,000 shares of Invitae common stock, a non-qualified
stock option to purchase 56,000 shares of Invitae common stock,
and 45,000 restricted stock units (RSUs). The stock options will
vest over a 4-year period, subject to continued service, with 25%
of each option award vesting on the one-year anniversary of her
appointment date and the remaining 75% of each option award
vesting monthly over the following three years. The shares of
common stock underlying the RSUs will vest in equal annual
installments over a 3-year period, subject to continued service,
with the first such installment vesting on May15, 2018. Each
equity award is subject to the terms and conditions of Invitaes
stock plan and the applicable stock award agreements. The
exercise price per share for the stock options will be equal to
the closing price of Invitaes common stock on the New York Stock
Exchange on June12, 2017. Ms.Guyer will also be eligible to
participate in Invitaes medical and other employee benefits
programs. Her employment is at will and she serves as an
executive officer at the discretion of Invitaes Board of
Directors.

Ms.Guyer has no family relationships with any of Invitaes
directors or executive officers, and she has no direct or
indirect material interest in any transaction required to be
disclosed to Item404(a) of RegulationS-K.

The foregoing summary of the Offer Letter is qualified in its
entirety by reference to the Offer Letter, a copy of which is
attached hereto as Exhibit 10.1 and incorporated herein by
reference.

On May25, 2017, Invitae issued a press release announcing the
senior management appointments disclosed in Item5.02 above. A
copy of such press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.

2

About Invitae Corporation (NYSE:NVTA)

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.

Invitae Corporation (NYSE:NVTA) Recent Trading Information

Invitae Corporation (NYSE:NVTA) closed its last trading session up +0.02 at 8.58 with 418,479 shares trading hands.